Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”), a diversified holding company (“HoldCo”) with three divisions: Healthcare, Building & Construction, and Real Estate & Investments, announced Tuesday it has entered into a Stock Purchase Agreement (the “Agreement”) to sell its DMS Health Technologies, Inc. (“DMS Health”) business unit. The purchase price under the Agreement is $18.75 million. DMS Health is the Mobile Healthcare business unit of the Company’s Healthcare division. DMS Health provides contract diagnostic imaging, including computerized tomography (“CT”), magnetic resonance imaging (“MRI”), positron emission tomography (“PET”), PET/CT, and nuclear medicine and healthcare expertise through a convenient, mobile service.
ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced Monday that it has completed the acquisition of Confucius Plaza Medical Laboratory Corp. (“Confucius Labs”), a Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory headquartered in Old Bridge, New Jersey. The approximately 4,000 square feet lab will provide a wide range of testing for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel (RPP) Molecular tests. The lab is owned by the Company’s new subsidiary, ProPhase Diagnostics, Inc., which was formed to aggregate medical testing business opportunities and expand the lab’s capabilities and capacity.
Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. (“Thrive”), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. The transaction was unanimously approved by both companies’ Boards of Directors and is anticipated to close during the first quarter of 2021, subject to regulatory approval and the satisfaction of other conditions.
ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today a definitive agreement to acquire a Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory. The lab is approved for a variety of important medical tests, including COVID-19 and Respiratory Pathogen Panel (RPP) Molecular tests. The lab will be owned by the Company’s new subsidiary, ProPhase Diagnostics, Inc., which has been formed to aggregate medical testing business opportunities and expand the lab’s capabilities and capacity. The lab being acquired by ProPhase Diagnostics is Confucius Plaza Medical Laboratory Corp. (“Confucius Labs”), and is headquartered in Old Bridge, New Jersey.
Clearview Capital Fund IV, L.P. and its affiliates (“Fund IV”) announced Wednesday the recapitalization, in partnership with management, of Capitol Imaging Services, LLC (“Capitol Imaging” or the “Company”). The transaction closed on October 1, 2020. Headquartered in Metairie, LA, Capitol Imaging is a leading provider of outpatient diagnostic imaging services in Louisiana and Alabama. Through its 20-freestanding facilities, the Company offers multi-modality capabilities including MRI, CT, and mammography, among others. The Company was founded by Dr. John Hamide who began acquiring diagnostic imaging centers in 2013. He and the management team have since completed 18 acquisitions, building one of the largest outpatient imaging platforms in the Gulf South region today.
Calibre Scientific is pleased to announce the acquisition of Lorne Laboratories Limited. Based in the United Kingdom, Lorne Laboratories is a specialty manufacturer of blood grouping reagents and diagnostic test kits for use in medical procedures, and a distributor of related laboratory equipment, enzymes, and biochemicals to supplement their main product lines. Lorne’s catalogue services governments, blood transfusion professionals, and hospital laboratories in over 100 countries, and they are an established critical partner of the UK’s National Health Service.
Empower Clinics Inc (OTCMKTS:EPWCF) (CSE:CBDT) revealed on Tuesday that through its wholly-owned subsidiary Empower Healthcare Assets Inc, it has completed the acquisition of Dallas, Texas-based Kai Medical Laboratory LLC from KTM5 Holdings LLC, NULV11 LLC and Consistent Investment Group LLC. Empower, which is one of the largest operators of medical health and wellness centers in the US, said Kai would help the company advance coronavirus (COVID-19) testing.
Matrix Medical Network® (Matrix) today announced the acquisition of Biocerna, a CLIA-certified and CAP-accredited laboratory dedicated to delivering clinical diagnostics tests to improve patients’ safety and quality of care. Biocerna has developed innovative assays, including for COVID-19 testing, that will allow Matrix to provide safe and expedient testing services to Matrix Medical Network and Matrix Clinical Solutions clients. Biocerna is located in Fulton, Maryland and has significant experience in clinical diagnostics and clinical testing support for clinical trials.
Northern Ohio Medical Specialists Healthcare, a value-based independent physician collective, recently merged with Precision Diagnostic Imaging and absorbed five former Cleveland-area PDI imaging centers. The centers, located in Warrensville Heights, Parma, Westlake, Middleburg Heights and Medina, will be changed to NOMS Allegiance Imaging in honor of PDI’s Georgia-based affiliate company, Allegiance Imaging & Radiology, according to a news release. NOMS Healthcare CEO Joshua G. Frederick said the partnership would further NOMS’ goal to maintain the independent nature of medicine.
American Laboratory Products Company, Ltd. (ALPCO), a specialty in vitro diagnostics company, announced Monday the majority recapitalization of the company by Ampersand Capital Partners. Ampersand’s investment will be used to support ALPCO’s worldwide growth initiatives, including the expansion of the company’s diagnostics test kit offering, broadening the company’s geographic presence, and fueling internal R&D product development and production operations. ALPCO is a Salem, NH-based in vitro diagnostics company that offers specialty immunoassay products (IVD and RUO) primarily focused on the clinical gastroenterology and diabetes research segments.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.